Drug Discovery World
JANUARY 4, 2023
China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM). The post China’s clinical trial activity in NAFLD increasing appeared first on Drug Discovery World (DDW). Not yet a DDW member? Remember Me.
Drug Discovery World
JANUARY 9, 2024
Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
MAY 9, 2024
Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery. Terms of the agreement were not disclosed. “We
Drug Discovery World
MAY 15, 2024
million by 2029, according to GlobalData. Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. DR is the main cause of vision loss in the working age population, often occurring in both eyes and progressing to blindness. In 2019 there were >14.2 Br J Clin Pharmacol. 2019;85(2):347-355.
Vial
MARCH 1, 2024
Growth factors for this market included the growing size of the pharmaceutical industry, the increasing number of clinical trials , substantial funds dedicated to pharma and biotech R&D, and the growing biosimilars and generics market. billion by 2029. By revenue, the largest CRO in the US was Thermo Fisher Scientific Inc.,
Drug Discovery World
OCTOBER 4, 2022
The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. . billion, compared to $19.9
The Pharma Data
OCTOBER 9, 2021
Safety profile of deucravacitinib consistent with other trials and no new safety signals reported. Deucravacitinib has been shown to be a highly effective, first-in-class, oral, selective TYK2 inhibitor in psoriasis and we have ongoing Phase 3 trials exploring the potential of deucravacitinib in psoriatic arthritis,” said Samit Hirawat, M.D.
Expert insights. Personalized for you.
130 
Let's personalize your content